A vaccine is in development against the “keystone bacteria” of periodontal disease. If successful, this vaccine could break the already identified developmental steps in the chain of host and bacteria reactions in the disease process which is known as periodontal disease. This vaccine would create the in host response [ i.e. patient response] the immunological ability to ‘nip in the bud’ the chain of invasion and inflammation which causes the damage, bleeding and bone loss which is known as periodontal disease. Periodontal disease remains the single most common cause of tooth loss today. This is a potentially change–bigger than huge–and would improve the dental health in ways we can only speculate about.
World-first therapeutic dental vaccine
Periodontitis therapeutic vaccine trials could start in 2018
December 5, 2016
University of Melbourne
A world-first vaccine that could eliminate or at least reduce the need for surgery and antibiotics for severe gum disease has been validated by new research.
Traditional treatments for periodontitis, such as surgery and antibiotics, cannot prevent a recurrence disease-causing bacteria.
Credit: Oral Health CRC University of Melbourne
A world-first vaccine developed by Melbourne scientists, which could eliminate or at least reduce the need for surgery and antibiotics for severe gum disease, has been validated by research published this week.
A team of dental scientists at the Oral Health CRC at the University of Melbourne has been working on a vaccine for chronic periodontitis for the past 15 years with industry partner CSL. Clinical trials on periodontitis patients could potentially begin in 2018.
Moderate to severe periodontitis affects one in three adults and more than 50 per cent of Australians over the age of 65. It is associated with diabetes, heart disease, rheumatoid arthritis, dementia and certain cancers. It is a chronic disease that destroys gum tissue and bone supporting teeth, leading to tooth loss.
The findings published in the journal NPJ Vaccines (part of the Nature series) represent analysis of the vaccine’s effectiveness by collaborating groups based in Melbourne and at Cambridge, USA.
The vaccine targets enzymes produced by the bacterium Porphyromonas gingivalis, to trigger an immune response. This response produces antibodies that neutralise the pathogen’s destructive toxins.
P. gingivalis is known as a keystone pathogen, which means it has the potential to distort the balance of microorganisms in dental plaque, causing disease.
CEO of the Oral Health CRC, Melbourne Laureate Professor Eric Reynolds AO, said it was hoped the vaccine would substantially reduce tissue destruction in patients harbouring P. gingivalis.
“We currently treat periodontitis with professional cleaning sometimes involving surgery and antibiotic regimes,” Professor Reynolds said.
“These methods are helpful, but in many cases the bacterium re-establishes in the dental plaque causing a microbiological imbalance so the disease continues.”
“Periodontitis is widespread and destructive. We hold high hopes for this vaccine to improve quality of life for millions of people.”
Eric C Reynolds et al. A therapeutic Porphyromonas gingivalis gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis. NPJ Vaccines, December 2016 DOI: 10.1038/npjvaccines.2016.22
Cite This Page:
University of Melbourne. “World-first therapeutic dental vaccine: Periodontitis therapeutic vaccine trials could start in 2018.” ScienceDaily. ScienceDaily, 5 December 2016. <www.sciencedaily.com/releases/2016/12/161205113748.htm>.